Creating new antimicrobial peptides to fight antibiotic-resistant bacteria
Official title: Development of novel, daptomycin-inspired antimicrobial peptides using non-canonical amino acids
Funded at Rowan University · NIH-11043618 · Data updated 2026-11-12
This study is exploring new types of antibiotics that could work better against tough bacteria that don't respond to regular treatments, aiming to help patients who need effective options for their infections.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rowan University NIH-funded |
| Lab location | 1 site (Glassboro, United States) |
| Project start | December 20, 2024 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $474,363 |
| NIH project number | 1R15AI188560-01 |
| Project ID | NIH-11043618 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
✕Less likely to help
Patients with infections that are not caused by bacterial pathogens may not benefit from this research.
What this research studies
This research focuses on developing innovative antimicrobial peptides inspired by daptomycin, a clinically approved antibiotic. By using non-canonical amino acids, the researchers aim to enhance the effectiveness of these peptides against antibiotic-resistant bacteria. The approach involves understanding how the structure of these peptides relates to their ability to disrupt bacterial membranes and bind calcium, which are crucial for their antimicrobial activity. Patients may benefit from new treatments that can effectively combat infections caused by resistant bacteria.
Why it matters
Potential benefit: If successful, this research could lead to new antimicrobial treatments that are effective against antibiotic-resistant infections.
How similar studies have gone: Other research has shown promise in developing antimicrobial peptides, suggesting that this approach could lead to significant advancements in treating resistant infections.
Where this research is happening
-
Rowan University
Glassboro, United States Active
Researchers
- Principal investigator: Caputo, Gregory Alexander — Rowan University
- Study coordinator: Caputo, Gregory Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.